TrialThe Lancet. Haematology2020

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

Courtney D DiNardo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.